|
|
|
|
|||||
|
|
|
New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves
Kenvue Inc. (NYSE:KVUE) is included among the 12 Most Promising Dividend Stocks According to Wall Street Analysts.
Kenvue Inc. (NYSE:KVUE) is a consumer health company that offers a wide range of over-the-counter medicines, personal care products, and wellness items. Its portfolio includes trusted brands such as Tylenol for pain relief, Neutrogena for skincare, and Listerine for oral health. The stock is down by over 24% since the start of 2025.
President Donald Trump recently claimed that Tylenol use during pregnancy could raise autism risk in children, prompting the FDA to consider warning labels and advise doctors to limit use. The comments caused Kenvue Inc. (NYSE:KVUE)’s stock to drop and spurred a wave of potential lawsuits. Kenvue and medical experts rejected the claim, noting there’s no proven link, and the FDA later clarified that acetaminophen remains the safest pain reliever for pregnant women. The controversy adds pressure to the company, which was already struggling with weak performance and leadership changes.
Despite recent challenges, Kenvue Inc. (NYSE:KVUE) remains an appealing option for income-focused investors due to its solid dividend yield. Following its spin-off from Johnson & Johnson, the company retained its recognition as a Dividend King, which makes it one of the most promising dividend stocks. In July, it raised its quarterly dividend by 1.2% to $0.2075 per share. The stock has a dividend yield of 5.16%, as of October 8.
While we acknowledge the potential of KVUE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 14 Best Food Dividend Stocks To Buy According to Analysts and Dividend Champions List: Top 15 Stocks to Buy.
Disclosure: None.
| 4 hours | |
| 9 hours | |
| Oct-08 | |
| Oct-03 | |
| Oct-01 | |
| Oct-01 | |
| Oct-01 | |
| Sep-29 | |
| Sep-26 | |
| Sep-26 | |
| Sep-26 | |
| Sep-26 | |
| Sep-26 | |
| Sep-26 | |
| Sep-24 |
RFK Jr.s Team Wanted to Tout an Autism Therapy. He Went After Tylenol Instead.
KVUE
The Wall Street Journal
|
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite